On Sunday, October 4, for the first time since mid-May, more than 10 thousand new cases of COVID-19 - 10 499 were recorded in Russia. According to the headquarters, 27.8% of new patients had no clinical manifestations of the disease.

In the previous two days, 9859 and 9412 cases were recorded.

In Russia, since the beginning of the epidemic, a total of 1,215,001 cases of COVID-19 have been identified.

At the same time, 979,143 patients (80.59%) recovered, including 3284 in the last day.

From complications that developed against the background of COVID-19 and concomitant diseases, 21,358 people died (1.76%).

Over the past day - 107.

The regions where the largest number of new cases were detected per day included Moscow (3327) and St. Petersburg (392), as well as Moscow (296), Rostov (234) Nizhny Novgorod (201), Voronezh (179) and Arkhangelsk (176 ) area.

According to Rospotrebnadzor, more than 47.6 million coronavirus tests have been carried out in the country.

226 thousand people remain under medical supervision.

The situation with COVID-19 in Moscow has stabilized somewhat, but hospitals continue to fill up with patients diagnosed with coronavirus.

Mayor of the capital Sergei Sobyanin announced this in an interview with the Russia 1 TV channel.

“We see how actively our hospitals are being loaded, the situation has stabilized somewhat, but the number of patients is still slowly but surely approaching 1,000 people a day, many of them are seriously ill,” Sobyanin said.

At the same time, the city authorities do not yet plan to massively transfer hospitals providing routine care to work exclusively with patients with COVID-19.

According to him, mobile hospitals "insure the situation".

The mayor also pointed out that Moscow has allocated more than 80 billion rubles to help businesses.

These funds were used to issue loans and restructure old debts.

“But the biggest and most effective help for business in today's conditions is to avoid their closure, to avoid serious restrictions,” added Sobyanin.

Also on russian.rt.com Moscow expands the list of free drugs for COVID-19 patients

According to him, the requirement for Moscow enterprises and organizations to transfer employees to remote work is due to the unwillingness to use "tougher measures."

As of October 4, a total of 303,940 cases of coronavirus were detected in Moscow (3327 in the last 24 hours). 

At the same time, 253,031 patients recovered for the entire time, while 5343 people died from complications associated with COVID-19 and other concomitant diseases.

Recall that from October 5 to October 28, employers in the capital are required to transfer at least 30% of employees to remote work, and enterprises that have this opportunity are recommended to send up to 50% of employees to remote work.

According to the expectations of the Moscow authorities, from Monday up to 2 million citizens will switch to remote work.

In addition, from October 5, the capital's schoolchildren will go on a vacation extended to two weeks due to the situation with COVID-19.

  • © Ilya Pitalev / RIA Novosti

In addition, the Federal Scientific Center for Research and Development of Immunobiological Preparations named after M.P.

Chumakov of the Russian Academy of Sciences reported that clinical trials of the COVID-19 vaccine developed at the center are scheduled to be completed in November.

“Of course, as soon as all clinical trials of the vaccine are completed, we can start using it.

We plan to complete the "clinic" in November ", - TASS quotes the general director of the center, corresponding member of the Russian Academy of Sciences Aidar Ishmukhametov.

In September, the Ministry of Health issued a permit to the Chumakov Center to conduct clinical trials of its own vaccine against coronavirus.

More than 3 thousand volunteers are taking part in the studies taking place in Kirov, St. Petersburg and Novosibirsk.

This is the third Russian development aimed at counteracting coronavirus infection.

On August 11, Russia was the first in the world to register a vaccine against the coronavirus infection COVID-19.

The drug, developed by the Gamaleya Research Center for Epidemiology and Microbiology, was named Sputnik V.

In addition, on September 30, the State Scientific Center for Virology and Biotechnology "Vector", which is developing its own vaccine against COVID-19 "EpiVacCorona", received the corresponding patents.

The registration process is expected to be completed by October 15th.